In the follicular lymphoma cohort of the BRUIN study of single-agent pirtobrutinib, why does the speaker say treatment duration exceeded median PFS?
Patients often relapsed slowly, so they could stay on the drug with stable, controlled disease and a good quality of life, even without complete disease eradication.
Most patients achieved complete metabolic responses, which were consolidated with continued maintenance therapy.
Protocol rules required patients to keep taking pirtobrutinib for a fixed period after progression before switching therapy.